Fortrea Holdings Inc.
FTRE
Positions held
Your positionsFTRE isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Fortrea Holdings Inc. is positioned in the biotechnology sector, which is known for its potential high returns due to innovation and advancements in healthcare.
- Revenue increased by 7% compared to the prior quarter, reaching $678 million.
- Gross margin improved to 20.5%, up from 19.4% in the previous quarter.
- The company has a high debt-to-equity ratio of 213.24, indicating potential financial instability.
- Fortrea reported a net income loss of $13.2 million in Q2 2026, continuing a trend of negative earnings.
- The operating margin remains low at 2.6%, reflecting challenges in profitability despite revenue growth.
Fundamentals
| Market cap | $1.94B | Enterprise value | $2.89B | Trailing P/E | — | Forward P/E | 17.79 |
| PEG | 0.34 | Price / book | 3.70 | Beta | 1.91 | Dividend yield | 0.00% |
| Revenue growth | -4.5% | Earnings growth | — | Gross margin | 19.3% | Operating margin | 2.6% |
| Profit margin | -3.2% | ROE | -15.3% | ROA | 0.6% | Debt / equity | 2.13 |
| Current ratio | 0.96 | Free cash flow | $278.86M | Analyst recommendation | buy | Mean target | $20.83 |
| 52w high | $23.51 | 52w low | $8.55 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $678M | $637M | $661M | $701M | $710M | — |
| Op margin | 2.6% | 0.5% | 1.3% | -0.5% | -1.5% | — |
| Net income | -$13.2M | -$23.6M | -$32.5M | -$15.9M | -$375M | — |
| Gross margin | 20.5% | 19.4% | 19.8% | 17.5% | 18.8% | — |
| Gross profit | $139M | $124M | $131M | $123M | $134M | — |
| Operating income | $17.5M | $3.3M | $8.8M | -$3.7M | -$10.9M | — |
- Revenue +7% vs prior quarter ($678M vs $636M).
- Gross margin 20.5% (was 19.4% prior quarter).
- Operating margin expanded to 2.6%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $2.7B | $2.7B | $2.8B | $2.8B |
| Op margin | -1.1% | -4.1% | 1.9% | 7.9% |
| Net income | -$986M | -$329M | -$25.2M | $186M |
| Gross margin | 18.5% | 19.8% | 20.8% | 25.5% |
| Gross profit | $504M | $534M | $591M | $724M |
| Operating income | -$30.6M | -$112M | $53.2M | $223M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Barclays Upgrades Fortrea to Overweight From Equalweight
2026-10-06 · Fortrea (FTRE) Stock Trades Up, Here Is Why
2026-10-06 · Barclays Upgrades Fortrea Holdings to Overweight From Equalweight
2026-10-05 · 2 Volatile Stocks to Consider Right Now and 1 We Find Risky
2026-10-05 · Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
2026-10-02 · 1 Momentum Stock to Research Further and 2 We Turn Down
2026-09-30 · 3 Healthcare Stocks That Concern Us
2026-09-27 · Fortrea (FTRE) Stock Could Be 46% Undervalued As Deal Questions Build
2026-09-23 · 2 Small-Cap Stocks to Research Further and 1 Facing Challenges
2026-09-22 · CRO consolidation keeps rolling. What does that mean for pharma?
2026-09-16 · 2 of Wall Street’s Favorite Stocks to Target This Week and 1 Facing Challenges
2026-09-10 · Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Price (daily)
Full chart · RSI · MACD · patterns